Nothing Special   »   [go: up one dir, main page]

SA520411108B1 - مركبات حلقية كبيرة واستخداماتها - Google Patents

مركبات حلقية كبيرة واستخداماتها

Info

Publication number
SA520411108B1
SA520411108B1 SA520411108A SA520411108A SA520411108B1 SA 520411108 B1 SA520411108 B1 SA 520411108B1 SA 520411108 A SA520411108 A SA 520411108A SA 520411108 A SA520411108 A SA 520411108A SA 520411108 B1 SA520411108 B1 SA 520411108B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
macrocyclic compounds
csf1r
met
present disclosure
Prior art date
Application number
SA520411108A
Other languages
English (en)
Inventor
افان دبليو روجيرس
هان زهانج
زهونجدزنج هوانج
جيفيرى ويتين
اكسين زهانج
جينجرونج جين سوى
دايونج زهاى
جينج ليو
جان ينج
وى دينج
Original Assignee
تورنينج بوينت ثيرابيوتيكس ، إنك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65039935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA520411108(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by تورنينج بوينت ثيرابيوتيكس ، إنك filed Critical تورنينج بوينت ثيرابيوتيكس ، إنك
Publication of SA520411108B1 publication Critical patent/SA520411108B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

يتعلق الكشف الحالي بمركبات حلقية كبيرة macrocyclic compounds معينة تُثبِّط سرطان ساركوماتويد كلوي Sarcomatoid renal carcinoma (SRC) و الانتقال من اللحمية المتوسطة إلى الظهارية Mesenchymal-to-Epithelial Transition (MET)، و/أو مستقبل عامل تحفيز المستعمرة 1 colony-stimulating factor 1 receptor (CSF1R)، تركيبات صيدلية pharmaceutical compositions تحتوي على تلك المركبات، وطرق استخدام تلك المركبات لعلاج السرطان cancer. شكل1
SA520411108A 2017-07-28 2020-01-21 مركبات حلقية كبيرة واستخداماتها SA520411108B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538193P 2017-07-28 2017-07-28
US201862700990P 2018-07-20 2018-07-20
PCT/US2018/043817 WO2019023417A1 (en) 2017-07-28 2018-07-26 MACROCYCLIC COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
SA520411108B1 true SA520411108B1 (ar) 2024-03-03

Family

ID=65039935

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411108A SA520411108B1 (ar) 2017-07-28 2020-01-21 مركبات حلقية كبيرة واستخداماتها

Country Status (26)

Country Link
US (3) US11286264B2 (ar)
EP (1) EP3658148B1 (ar)
JP (2) JP7224334B2 (ar)
KR (1) KR102645316B1 (ar)
CN (1) CN111182903A (ar)
AU (1) AU2018306328B2 (ar)
BR (1) BR112020001695A2 (ar)
CA (1) CA3069232A1 (ar)
CL (1) CL2020000169A1 (ar)
CO (1) CO2020000633A2 (ar)
DK (1) DK3658148T3 (ar)
FI (1) FI3658148T3 (ar)
IL (1) IL271964B1 (ar)
LT (1) LT3658148T (ar)
MY (1) MY201925A (ar)
PE (1) PE20200700A1 (ar)
PH (1) PH12020500033A1 (ar)
PL (1) PL3658148T3 (ar)
PT (1) PT3658148T (ar)
RS (1) RS65884B1 (ar)
SA (1) SA520411108B1 (ar)
SG (1) SG11202000356VA (ar)
SI (1) SI3658148T1 (ar)
TW (1) TWI818917B (ar)
UA (1) UA126158C2 (ar)
WO (1) WO2019023417A1 (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3636649T3 (fi) 2014-01-24 2024-05-02 Turning Point Therapeutics Inc Diaryylimakrosyklejä proteiinikinaasien modulaattoreina
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
JP7128345B2 (ja) 2018-04-25 2022-08-30 プライムジーン（ベイジン）カンパニー リミテッド ジアリール大員環化合物、医薬組成物及びその用途
MX2021004538A (es) 2018-10-22 2021-09-10 Esker Therapeutics Inc Inhibidores de tyk2 y sus usos.
BR112021017996A2 (pt) * 2019-03-11 2021-11-16 Esker Therapeutics Inc Inibidores de tyk2 e seus usos
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
JP2023515687A (ja) * 2020-03-02 2023-04-13 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環状化合物の治療使用
CN113754682B (zh) * 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 具有大环结构的化合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN116829562A (zh) * 2021-02-10 2023-09-29 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
WO2022246092A1 (en) * 2021-05-21 2022-11-24 Blossomhill Therapeutics, Inc. Macrocyclic compounds for treating disease
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
EP4433462A1 (en) * 2021-11-16 2024-09-25 Prodeg, LLC Usp9x inhibitors
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425736T2 (de) 1993-03-25 2001-04-12 Pharmacia & Upjohn Co., Kalamazoo Formyl- oder Cyano- substituierte Indolderivate mit dopaminergischer Wirkung
CZ291950B6 (cs) 1993-12-07 2003-06-18 Eli Lilly And Company Bis-indolmaleinimidy, jako inhibitory proteinové kinázy C, léčivo, farmaceutický prostředek s jejich obsahem a jejich použití
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU2001286768A1 (en) 2000-08-25 2002-03-04 Sloan-Kettering Institute For Cancer Research Novel macrocycles and uses thereof
ES2245994T3 (es) 2000-12-08 2006-02-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos macro-heterociclicos utilizados como inhibidores de quinasa.
WO2010028116A1 (en) 2008-09-08 2010-03-11 Merck Serono S.A. Macrocyclics pyrimidines as aurora kinase inhibitors
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
TWI639605B (zh) 2008-10-22 2018-11-01 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
KR101686685B1 (ko) 2008-10-31 2016-12-14 제넨테크, 인크. 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CN102971322B (zh) 2010-05-20 2016-02-17 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2012168986A1 (ja) 2011-06-10 2012-12-13 株式会社メンテック 汚染防止剤組成物
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
MX2014001944A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c.
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
EP2822953B9 (en) 2012-03-06 2017-06-21 Pfizer Inc Macrocyclic derivatives for the treatment of proliferative diseases
NZ630721A (en) 2012-03-09 2016-12-23 Lexicon Pharmaceuticals Inc Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
ES2676826T3 (es) 2012-03-09 2018-07-25 Lexicon Pharmaceuticals, Inc. Compuestos basados en imidazo[1,2-b]piridazina, composiciones que los comprenden y usos de los mismos
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
FI3636649T3 (fi) 2014-01-24 2024-05-02 Turning Point Therapeutics Inc Diaryylimakrosyklejä proteiinikinaasien modulaattoreina
TWI688567B (zh) * 2014-09-11 2020-03-21 美商特普醫葯公司 作為蛋白質激酶之調節劑的二芳基巨環
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
HRP20240780T1 (hr) * 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
EP3490564A4 (en) * 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
CN109956957B (zh) 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
DK3783000T3 (da) 2018-04-18 2022-08-01 Hitgen Inc Makrocyklisk kinasehæmmer

Also Published As

Publication number Publication date
US11155563B2 (en) 2021-10-26
IL271964B1 (en) 2024-08-01
EP3658148A1 (en) 2020-06-03
AU2018306328A1 (en) 2020-01-16
US20200157119A1 (en) 2020-05-21
UA126158C2 (uk) 2022-08-25
CA3069232A1 (en) 2019-01-31
US11286264B2 (en) 2022-03-29
FI3658148T3 (fi) 2024-09-20
KR20200034998A (ko) 2020-04-01
US11981684B2 (en) 2024-05-14
CL2020000169A1 (es) 2020-08-14
JP7224334B2 (ja) 2023-02-17
US20220324879A1 (en) 2022-10-13
WO2019023417A1 (en) 2019-01-31
PH12020500033A1 (en) 2020-09-28
IL271964A (en) 2020-02-27
PT3658148T (pt) 2024-08-26
JP7554300B2 (ja) 2024-09-19
EP3658148A4 (en) 2021-04-28
CO2020000633A2 (es) 2020-01-31
EP3658148B1 (en) 2024-07-10
SG11202000356VA (en) 2020-02-27
JP2023065403A (ja) 2023-05-12
AU2018306328B2 (en) 2023-03-09
RS65884B1 (sr) 2024-09-30
TW201920198A (zh) 2019-06-01
KR102645316B1 (ko) 2024-03-07
MY201925A (en) 2024-03-23
PL3658148T3 (pl) 2024-10-07
PE20200700A1 (es) 2020-06-23
BR112020001695A2 (pt) 2020-07-21
DK3658148T3 (da) 2024-10-07
LT3658148T (lt) 2024-09-10
TWI818917B (zh) 2023-10-21
JP2020528907A (ja) 2020-10-01
US20210214373A1 (en) 2021-07-15
CN111182903A (zh) 2020-05-19
SI3658148T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12019501812A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
PH12016501578A1 (en) Pharmaceutical compounds
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
MX2017012553A (es) Compuestos espirociclicos.
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
EA201790851A1 (ru) Способы предотвращения, уменьшения и лечения макулодистрофии
PH12017501897A1 (en) 2-thiopyrimidinones
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.